---
id: 019
title: Vancomycin AUC-Based Monitoring (2020 Guidelines)
category: antimicrobials
subcategory: pharmacokinetics_pharmacodynamics
tags: [vancomycin, AUC/MIC, MRSA, monitoring, 2020-guidelines]
difficulty: medium
---

## Question

What are the **2020 ASHP/IDSA/PIDS/SIDP vancomycin guidelines** regarding therapeutic monitoring? Why did they move away from trough-based dosing?

## Answer

### **2020 Guideline Recommendations:**

| Parameter | Target | Notes |
|-----------|--------|-------|
| **AUC₂₄/MIC** | **400-600 mg·h/L** | Primary target for serious MRSA infections |
| **Assumed MIC** | 1 mg/L | For empiric dosing (unless actual MIC available) |
| **Target AUC₂₄** | 400-600 mg·h/L | Based on assumed MIC of 1 |
| **Trough levels** | No longer recommended | Replaced by AUC-based monitoring |
| **Timing** | Within 24-48 hours | Achieve target quickly |

### **Rationale for Change from Trough to AUC:**

1. **Reduced nephrotoxicity:**
   - Trough-based dosing (15-20 mg/L) associated with ↑ AKI
   - AUC-guided dosing has less nephrotoxicity while maintaining efficacy

2. **Better efficacy predictor:**
   - AUC/MIC ≥400 correlates with clinical success for MRSA bacteremia/pneumonia
   - Trough levels poorly predict actual drug exposure (AUC)

3. **Avoids supratherapeutic exposure:**
   - High troughs (>20 mg/L) often led to AUC >600 → toxicity

### **Dosing Strategy:**
- Adults: 15-20 mg/kg IV q8-12h (max 2g/dose)
- Use **Bayesian software** (e.g., PrecisePK, DoseMe) for AUC calculation
- At least **2 levels** (peak and trough) required for accurate AUC estimation

## Key Points

- Guidelines apply to **serious MRSA infections** (bacteremia, pneumonia, osteomyelitis, endocarditis)
- Simple infections (cellulitis, UTI) may not require monitoring
- Loading dose: 25-30 mg/kg for severe infections

## Sources

- [2020 ASHP/IDSA/PIDS/SIDP Vancomycin Guidelines]
- [PMC10201943: Safety and Efficacy of AUC vs Trough-Guided Monitoring]
- [Sanford Guide: Vancomycin AUC24 Explained]

## Media

N/A
